Haircafe's video: Does finasteride cause male breast cancer

Linked videos: Optimal dose of finasteride: https://youtu.be/15PHO1m6D-c Vioxx, finasteride and Merck lawsuits: https://youtu.be/5iR4mQaXyYQ Finasteride in women: https://youtu.be/74zQFT4ZmxU Sources: 1. Vermeulen A, Giagulli VA, De Schepper P, Buntinx A. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia. Eur Urol. 1991;20 Suppl 1:82-86. doi:10.1159/000471752 2. Castro-Magana M, Angulo M, Fuentes B, et al. Effect of finasteride on human testicular steroidogenesis. J Androl. 1996;17(5):516-521. 3. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557-563. doi:10.1056/NEJM199802263380901 4. Uygur MC, Arik AI, Altuğ U, Erol D. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids. 1998;63(4):208-213. doi:10.1016/s0039-128x(98)00005-1 5. McConnell JD, Roehrborn CG, Bautista OM, et al. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. N Engl J Med. 2003;349(25):2387-2398. doi:10.1056/NEJMoa030656 6. Roehrborn CG, Lee M, Meehan A, Waldstreicher J, PLESS Study Group. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology. 2003;62(5):894-899. doi:10.1016/s0090-4295(03)00661-7 7. Lee SC, Ellis RJ. Male Breast Cancer During Finasteride Therapy. JNCI Journal of the National Cancer Institute. 2004;96(4):338-339. doi:10.1093/jnci/djh062 8. Shenoy NK, Prabhakar SM. Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link? J Cutan Aesthet Surg. 2010;3(2):102-105. doi:10.4103/0974-2077.69022 9. Bird ST, Brophy JM, Hartzema AG, Delaney JAC, Etminan M. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. J Urol. 2013;190(5):1811-1814. doi:10.1016/j.juro.2013.04.132 10. Duijnhoven RG, Straus SMJM, Souverein PC, et al. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control. 2014;25(11):1577-1582. doi:10.1007/s10552-014-0455-6 11. Wiebe JP, Rivas MA, Mercogliano MF, Elizalde PV, Schillaci R. Progesterone-induced stimulation of mammary tumorigenesis is due to the progesterone metabolite, 5α-dihydroprogesterone (5αP) and can be suppressed by the 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol. 2015;149:27-34. doi:10.1016/j.jsbmb.2015.01.004 12. Hagberg KW, Divan HA, Fang SC, Nickel JC, Jick SS. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Epidemiol. 2017;9:83-91. doi:10.2147/CLEP.S124674 13. Kim MW, Park HS, Park JS, Koh SJ, Cho S. Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review. Ann Dermatol. 2017;29(4):525-528. doi:10.5021/ad.2017.29.4.525 14. Meijer M, Thygesen LC, Green A, et al. Finasteride treatment and male breast cancer: a register‐based cohort study in four Nordic countries. Cancer Med. 2017;7(1):254-260. doi:10.1002/cam4.1273 15. Kjærulff TM, Ersbøll AK, Green A, et al. Finasteride Use and Risk of Male Breast Cancer: A Case–Control Study Using Individual-Level Registry Data from Denmark, Finland, and Sweden. Cancer Epidemiology, Biomarkers & Prevention. 2019;28(5):980-986. doi:10.1158/1055-9965.EPI-18-0904 16. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873. doi:10.1136/bmj.m3873